Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDI-M402
- Development stage
- Preclinical
- Lead developer
- Empire Discovery Institute
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
EDI-M402 is a preclinical-stage immunotherapy platform developed by the Empire Discovery Institute. It utilizes phosphatidylserine-containing liposomes to induce antigen-specific immune tolerance. By mimicking the natural process of apoptotic cell clearance (efferocytosis), where phosphatidylserine acts as an "eat-me" signal that promotes an anti-inflammatory environment, the platform aims to reprogram the immune system to tolerate specific autoantigens. This approach is intended for the treatment of various autoimmune diseases by preventing the immune system from attacking the body's own tissues without causing broad immunosuppression.
Beyond the preview
Go deeper on EDI-M402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDI-M402.